홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Metyrosine

HCID 441350
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
672-87-7
표준 SMILES
C[C@](N)(Cc1ccc(O)cc1)C(=O)O
InChIKey
NHTGHBARYWONDQ-JTQLQIEISA-N
분자식
C10H13NO3
평균 분자량
195.21 g/mol
단동위원소 질량
195.08954328

개요

Alpha-methyl-L-tyrosine is an L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. It has a role as an antihypertensive agent and an EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor. It is a L-tyrosine derivative and a non-proteinogenic L-alpha-amino acid.

이름 및 식별자

우선 이름
Metyrosine
IUPAC
(2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
영어명
alpha-Methyl-L-p-tyrosine
분자식
C10H13NO3
분자량
195.22

이름 및 동의어

METYROSINE672-87-7MetirosineDemserMetirosina(2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid(S)-alpha-MethyltyrosineL-alpha-MethyltyrosineMetirosinum(-)-alpha-Methyl-L-tyrosineAlpha-Methyl-L-P-TyrosineMK-781
이름 더 보기
α-Methyl-L-tyrosineα-Me-Tyr-OHAMPTL-AMPTL-α-MTa-Me-Tyr-OHL-Metyrosine
DTXSID6023315DOQ0J0TPF7CHEBI:6912L-588357-0DTXCID203315methyl-tyrosineRefChem:56543alpha-Methyltyrosine, (L)-

데이터베이스 식별자

CAS
672-87-7
PubChem CID
441350
DTXSID
DTXSID6023315
ChEMBL
CHEMBL1200862
ChEBI
CHEBI:6912
UNII
DOQ0J0TPF7
EC Number
211-599-5
Nikkaji
J9.465J

물성

구조 계산 물성

XLogP
-1.6
극성 표면적
83.6 Ų
수소 결합 공여자 수
3
수소 결합 수용자 수
4
회전 가능 결합 수
3
무거운 원자 수
14
형식 전하
0
복잡도
211

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
LogP-1.7
Solubility · 2건

Very slightly soluble

2.48e+00 g/L

Human Drugs · 2건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point312.5 °C
Physical DescriptionSolid

물리화학적 성질

녹는점
320 · 320-340°C dec.
끓는 점
383.7 · 383.7±32.0 °C(Predicted)
밀도
1.283 · 1.283±0.06 g/cm3(Predicted)
저장 조건
-20 °C · -20°C
용해도
산성 용액(약간 용해됨)
물리적 상태
가루
산도 계수 (pKa)
2.7 · pKa 2.7 (Uncertain);10.1 (Uncertain)
색상
흰색에서 연한 노란색
Merck

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P301+P317, P304+P340, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (100%)

독성 정보

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Metyrosine

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

안전 데이터

wgk
3
tsca
No
HS 번호
2922504500
risk_code
22-38-40-48/20/22
safety_code
22-24/25
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

ATC Code · 2건

C - Cardiovascular system

QC - Cardiovascular system

Pharmacodynamics · 1건

In patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of one to four grams of metyrosine per day has reduced catecholamine biosynthesis from about 35 to 80 percent as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pretreatment levels within three to four days after metyrosine is discontinued. Most patients with pheochromocytoma treated with metyrosine experience decreased frequency and severity of hypertensive attacks with their associated headache, nausea, sweating, and tachycardia. In patients who respond, blood pressure decreases progressively during the first two days of therapy with metyrosine; after withdrawal, blood pressure usually increases gradually to pretreatment values within two to three days.

Mechanism of Action · 1건

Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines and their synthesis. This consequently, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body,usually measured as decreased urinary excretion of catecholamines and their metabolites. One main end result of the catecholamine depletion is a decrease in blood presure.

Biological Half-Life3.4 to 3.7 hours
Metabolism/MetabolitesLittle biotransformation, with catechol metabolites accounting for less than 1% of the administered dose.
FDA Pharmacological Classification · 6건

DOQ0J0TPF7

METYROSINE

관련 반응

5건
반응 기록 만들기
HRID 78951 반응식
HRID 78951생성물로
HRID 78954 반응식
HRID 78954생성물로
HRID 1980390 반응식
HRID 1980390생성물로
HRID 2230273 반응식
HRID 2230273반응물로
HRID 2289418 반응식
HRID 2289418반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
13 · 13,6183
BRN
2368400 · 2368400
InChI
InChI=1/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/s3
InChIKey
NHTGHBARYWONDQ-JTQLQIEISA-N
SMILES
C(C1C=CC(O)=CC=1)[C@@](N)(C)C(=O)O |&1:8,r|

화학적 성질

White Solid

Established Pharmacologic Class [EPC] - Catecholamine Synthesis Inhibitor

Mechanisms of Action [MoA] - Catecholamine Synthesis Inhibitors

Metyrosine is a Catecholamine Synthesis Inhibitor. The mechanism of action of metyrosine is as a Catecholamine Synthesis Inhibitor.

METYROSINE

MeSH Pharmacological ClassificationCompounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Absorption, Distribution and Excretion · 2건

Well absorbed from the gastrointestinal tract.

Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.

응용 분야 · 3건

용도A tyrosine hydroxylase inhibitor. An antihypertensive in pheochromocytoma

용도Metyrosine is the α-methyl derivative of tyrosine. It competitively inhibits tyrosine hydroxylase action, thus reducing the formation of epinephrine and norepinephrine. It is used for treating patients with pheochromocytoma, in cases where a rise in the level of catecholamines is observed.

일반 설명Metyrosine (α-Methyl-L-tyrosine, Demser). Althoughinhibition of any of the three enzymes involved in CA biosynthesisshould decrease CAs, inhibitors of the first andthe rate-limiting enzyme TH would be the most effective.As such, metyrosine is a much more effective competitiveinhibitor of E and NE production than agents that inhibitany of the other enzymes involved in CA biosynthesis. Itis often possible to “fool” the enzymes into accepting astructurally similar and unnatural substrate such as metyrosine.Metyrosine differs structurally from tyrosine onlyin the presence of an α-methyl group . It is oneexample of a CA-biosynthesis inhibitor in clinical use.Although metyrosine is used as a racemic mixture, it is the (-)isomer that possesses the inhibitory activity.Metyrosine, which is given orally in dosages ranging from 1 to 4 g/day, is used principally for the preoperative managementof pheochromocytoma, chromaffin cell tumorsthat produce large amounts of NE and E. Although theseadrenal medullary tumors are often benign, patients frequentlysuffer hypertensive episodes. Metyrosine reducesthe frequency and severity of these episodes by significantlylowering CA production (35%–80%). The drug ispolar (log P=0.73) and excreted mainly unchanged in theurine. Because of its limited solubility in water caused byintramolecular bonding of the zwitterions, crystalluria is apotential serious side effect. It can be minimized by maintaininga daily urine volume of more than 2 L. Inhibitors ofCA synthesis have limited clinical utility because suchagents nonspecifically inhibit the formation of all CAs andresult in many side effects. Sedation is the most commonside effect of this drug.A similar example is the use of α-methyl-m-tyrosine inthe treatment of shock. It differs structurally from metyrosineonly in the presence of m-OH instead of p-OH inmetyrosine. This unnatural amino acid is accepted by the enzymesof the biosynthetic pathway and converted tometaraminol (an α-agonist).

추가 설명 · 1건

정의ChEBI: An L-tyrosine derivative that consists of L-tyrosine bering an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is us d to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.